Advanced Search

 

Study ID Status Title Patient Level Data
SAM40086 Completed A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic) Study Listed on ClinicalStudyDataRequest.com
SAM40088 Completed Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long-acting inhaled beta2-agonist
SAM40090 Completed A Twelve Week Multi-Centre, Randomized, Double-Blind, Parallel Group, Comparative Trial of Advair 50/100 mcg Diskus Inhalation Device BID versus Flovent 250 mcg Diskus Inhalation Device BID in Adolescents and Adults with Persistent Asthma (Program of Advair Control and Effectiveness – Advair Low ...
SAM40092 Completed Effect of salmeterol/fluticasone propionate combination product on seasonal changes in airway responsiveness and exhaled nitric oxide in subjects with pollen-induced asthma.
SAM40100 Completed Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily. Study Listed on ClinicalStudyDataRequest.com
SAM40101 Completed A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. Study Listed on ClinicalStudyDataRequest.com
SAM40104 Completed Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily Study Listed on ClinicalStudyDataRequest.com
SAM40114 Completed A post-marketing surveillance study on the real world use of SFC (Salmeterol /Fluticasone Propionate Combination) in Ireland
SAM40116 Completed A 12-week multi-centre, randomised, double blind, parallel group study to compare the efficacy of salmeterol/fluticasone propionate (Seretide TM) 50/100 mcg or 50/250 mcg twice daily and fluticasone propionate (Flixotide TM) 250 mcg or 500 mcg twice daily via the Diskus TM in subjects with asthm ...
SAM40120 Completed A phase IV, multi-centre, double-blind, parallel group, randomised study comparing Seretide (50/100mcg bd) via the Evohaler (MDI-HFA) with Flixotide (250mcg bd) via the Evohaler (MDI-HFA) in asthmatics with significant smoking history
SAM40121 Completed Summary of the efficacy and safety and safety of salmeterol 50mcg and fluticasone propionate 100mcg administered in Diskus Dry Powder Inhaler twice daily in steroid experienced children with reversible airways obstruction
SAM49071 Completed A multicentre, stratified, randomised, double blind, parallel group trial to evaluate whether a treatment strategy based on aiming for Total Control results in better AHR than a treatment strategy based on maintaining Well Control
SAS10001 Completed Systemic pharmacodynamic effects of salmeterol, delivered over 3 hours in a cumulative dosing series, from salmeterol/fluticasone propionate/HFA134A metered-dose inhaler (MDI) to total dose 400/2000mcg, in comparison with salmeterol/P 11/12 MDI to total dose 400mcg, and placebo, in a randomised, ...
SAS10002 Completed A Four-Period Crossover, Placebo Controlled Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of Salmeterol/Fluticasone Propionate/HFA134A via MDI in Combination Compared With Salmeterol/P11/12 and Fluticasone Propionate/P11/12 via MDI Administered Individually.
SAS10003 Completed A Double-Blind, Placebo-Controlled Four Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Fluticasone Propionate and Salmeterol With Increasing Dose Strengths of the Fluticasone Propionate/Salmeterol/HFA134A MDI Combination Product
SAS10005 Completed A part-randomized, single-blind, placebo-controlled, five-way crossover study to assess the absolute bioavailability, relative bioavailability and comparative pharmacodynamics of fluticasone propionate from ADVAIR HFA MDI, ADVAIR DISKUS, FP CFC MDI and intravenous FP and to assess the relative b ...
SAS10006 Completed A 12-week, randomized, double-blind, placebo-controlled, 3-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate (FP) administered twice daily via the Diskus (FP 100mcg) and the FP/Salmeterol (SALM) combination product (FP 100mcg/SALM 50mcg) administered twice daily via the Diskus Study Listed on ClinicalStudyDataRequest.com
SAS10007 Completed A 16-week, randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in adult subjects with asthma aged 18-55 years to examine the pharmacodynamics and pharmacokinetics of fluticasone propionate and salmeterol administered via FP/Salmeterol (SALM) combination product Diskus (FP 250mcg/SALM 50mcg), FP/Salmeterol combination metered dose inhaler (MDI) (FP 110mcg/SALM 21mcg) containing the hydrofluoroalkane (HFA) propellant, GR106642X, and FP MDI (FP 110mcg) containing HFA propellant Study Listed on ClinicalStudyDataRequest.com
SAS10013 Completed An open, parallel group, repeat dose study to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of salmeterol and fluticasone propionate delivered as SERETIDE DISKUS (50/250mcg twice daily [b.i.d.]) in Japanese and Caucasian asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
SAS10014 Completed A study to compare the systemic pharmacodynamic effects and pharmacokinetics of SERETIDE DISKUS/ACCUHALER Inhaler (200/1000mcg) with salmeterol alone (200mcg) and fluticasone propionate alone (1000mcg) in healthy Japanese subjects Study Listed on ClinicalStudyDataRequest.com
SAS10015 Completed A randomised, double-blind, double-dummy, cross-over comparison of the salmeterol/fluticasone propionate combination product (50/250mg strength) twice daily via one Diskus inhaler with salmeterol 50mg twice daily via one Diskus inhaler plus fluticasone propionate 250mg twice daily via a second Diskus inhaler in Japanese and Caucasian asthmatics Study Listed on ClinicalStudyDataRequest.com
SAS10016 Completed A 4-week, randomized, double-blind, placebo run-in, parallel-group study in pediatric subjects with asthma aged 4-11 years to examine the pharmacodynamics and pharmacokinetics of the fluticasone propionate (FP) and salmeterol (SALM) combination product administered twice daily via the Diskus (FP 100mcg/SALM 50mcg) and the FP Diskus (FP 100mcg) Study Listed on ClinicalStudyDataRequest.com
SAS10017 Completed Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Compare the Relative Bioavailability and Pharmacodymanics of Fluticasone Propionate from Two Batches of Seretide MDI with Different in vitro Characteristics Study Listed on ClinicalStudyDataRequest.com
SAS10019 Completed A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma Study Listed on ClinicalStudyDataRequest.com
SAS10020 Completed A single dose, randomized, double-blind, 2-way crossover study to assess the safety, tolerability, pharmacodynamics and pharmacokinetic profile of SERETIDE™ 50/50 compared to concurrent administration of individual FP 50 and SALM 50 inhalers in healthy subjects aged 18 – 55 years. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.